[Prostate cancer. Introduction].
Basic, epidemiological and clinical issues to be solved on prostate cancer were discussed as a preface. Sharp increase of prostate cancer incidence in Asian countries, almost constant level of latent cancer are intriguing epidemiological and pathological issues. Treatment of locally advanced prostate cancer, hormone-refractory prostate cancer has been a long-standing clinical challenge. New radiotherapy is expected for further advancement. Heterogeneity, clonility, multiplicity of prostate cancer are interesting pathological challenges.
Kakizoe
Tadao
T
National Cancer Center.
D058891:5-alpha Reductase Inhibitors; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D018752:Diet, Fat-Restricted; D014676:Diet, Vegetarian; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D018120:Finasteride / Q000009:adverse effects / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D011878:Radiotherapy; D012643:Selenium / Q000627:therapeutic use; D024502:alpha-Tocopherol / Q000627:therapeutic use
D058891:5-alpha Reductase Inhibitors; D018931:Antineoplastic Agents, Hormonal; D004791:Enzyme Inhibitors; D018120:Finasteride; D024502:alpha-Tocopherol; D012643:Selenium